Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Glutamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamine SCHEMBL2143276 | 1.00 | GSR (0.77) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL28030897 | 1.00 | GSR (0.77) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL1812362 | 1.00 | GSR (0.77) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL5461649 | 1.00 | GSR (0.77) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL12468749 | 1.00 | GSR (0.77) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL14485689 | 0.98 | GSR (0.74) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL29022149 | 0.98 | GSR (0.74) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL19743900 | 0.98 | GSR (0.74) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL29022151 | 0.98 | GSR (0.74) | GSRBLMKMT2AALOX15PMP22 | |
| Glutamine SCHEMBL19743899 | 0.98 | GSR (0.74) | GSRBLMKMT2AALOX15PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469687-B2 | Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2016-10-18 | — | — | US | disclosed |
| US-9453071-B2 | Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2016-09-27 | — | — | US | disclosed |
| US-20150299308-A1 | BINDING PARTNERS OF THE PLACENTAL GROWTH FACTOR, ESPECIALLY ANTIBODIES DIRECTED AGAINST THE PLACENTAL GROWTH FACTOR, AND PRODUCTION AND USE THEREOF | SIEMENS HEALTHCARE DIAGNOSTICS (DE) | 2015-10-22 | — | — | US | disclosed |
| WO-2012051282-A2 | PIWIL2-LIKE (PL2L) PROTEINS-TARGETED CANCER DIAGNOSIS AND THERAPY | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-04-19 | — | — | WO | disclosed |
| US-8063180-B2 | Antibodies directed against prothrombin fragment F1+2, the preparation and use thereof | Seimens Healthcare Diagnostics Products GmbH (DE) | 2011-11-22 | — | — | US | disclosed |
| US-7951910-B2 | Peptides with the marburg I polymorphism of factor VII-activating protease (FSAP) and their preparation and uses | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-7795403-B2 | Antibodies directed against prothrombin fragment F1+2, the preparation and use thereof | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2010-09-14 | — | — | US | disclosed |
| US-20100158932-A1 | Antibodies directed against prothrombin fragment F1+2, the preparation and use thereof | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH | 2010-06-24 | — | — | US | disclosed |
| US-20100145009-A1 | ANTIBODIES WHICH ARE DIRECTED AGAINST THE MARBURG I POLYMORPHISM OF FACTOR VII-ACTIVATING PROTEASE (FSAP), AND THEIR PREPARATION AND USE | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH | 2010-06-10 | — | — | US | disclosed |
| US-7622558-B2 | Antibodies which are directed against the Marburg I polymorphism of factor VII-activating protease (FSAP), and their preparation and use | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2009-11-24 | — | — | US | disclosed |
| US-6905687-B2 | Human procalcitonin and the preparation and use thereof | DADE BEHRING MARBURG GMBH (DE) | 2005-06-14 | — | — | US | disclosed |
| US-20050113562-A1 | Antibodies directed against prothrombin fragment F1+2, the preparation and use thereof | DADE BEHRING MARBURG GMBH | 2005-05-26 | — | — | US | disclosed |
| US-20030181662-A1 | Human procalcitonin and the preparation and use thereof | DADE BEHRING MARBURG GMBH (GERMANY) | 2003-09-25 | — | — | US | disclosed |
| US-20030108550-A1 | Anti-procalcitonin antibodies and the preparation and use thereof | DADE BEHRING MARBURG GMBH | 2003-06-12 | — | — | US | disclosed |
| US-6562946-B2 | Polypeptide; for use as diagnostic tool in detection of sepsis and cancer | DADE BEHRING MARBURG GMBH (DE) | 2003-05-13 | — | — | US | disclosed |
| US-6451311-B2 | AN ANTIBODY WHICH BINDS PROCALCITONIN BUT NOT FREE CALCITONIN, FREE KATACALCIN AND FREE N-PROCALCITONIN; USED AS AN IN VITRO OR IN VIVO DIAGNOSTIC AGENT | DADE BEHRING MARBURG GMBH (DE) | 2002-09-17 | — | — | US | disclosed |
| US-20020052471-A1 | Human procalcitonin and the preparation and use thereof | DADE BEHRING MARBURG GMBH. | 2002-05-02 | — | — | US | disclosed |
| US-20010007020-A1 | ANTIBODIES THAT BIND TO THE NIDOGEN-BINDING DOMAIN OF LAMININ, THEIR PRODUCTION AND USE | HOECHST AKTIENGESELLSCHAFT | 2001-07-05 | — | — | US | disclosed |
| US-20010007022-A1 | Anti-procalcitonin antibodies and the preparation and use thereof | DADE BEHRING MARBURG GMBH. | 2001-07-05 | — | — | US | disclosed |
| US-5514599-A | Antibodies against highly conserved amino acid sequences of insulin a process for the preparation of these antibodies and the use thereof in immunoassays | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181662-A1 | Human procalcitonin and the preparation and use thereof | CALCA, CALCB, CALCRL | GSR 4574/4885BLM 4486/4885KMT2A 4696/4885 |
| US-20150299308-A1 | BINDING PARTNERS OF THE PLACENTAL GROWTH FACTOR, ESPECIALLY ANTIBODIES DIRECTED AGAINST THE PLACENTAL GROWTH FACTOR, AND PRODUCTION AND USE THEREOF | PGF, HDGF, HDGFL3 | GSR 4560/4885BLM 4622/4885KMT2A 3838/4885 |
| US-20020052471-A1 | Human procalcitonin and the preparation and use thereof | CALCA, CALCB, CALCRL | GSR 4574/4885BLM 4486/4885KMT2A 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.